Navigation Links
Surveyed U.S. Neurologists Would Prescribe Biogen Idec's Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
Date:4/8/2013

BURLINGTON, Mass., April 8, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. neurologists indicated that they would prescribe Biogen Idec's Tecfidera to 20 percent of their patients with relapsing-remitting multiple sclerosis (RR-MS). Decision Resources forecasts that Tecfidera will earn a patient share similar to surveyed neurologists' estimate in the U.S. RR-MS market by 2021, owing to its robust efficacy—specifically, a greater reduction in annualized relapse rate (ARR) relative to first-line agents—and a strong safety profile relative to the most effective current therapies, such as Biogen Idec's Tysabri.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase 2013 report entitled Where Do Physicians and Payers Signal the Greatest Need—and Greatest Opportunity—for New Therapeutic Advances? also finds that, according to insights from surveyed U.S. and European neurologists and managed care organizations' (MCO) pharmacy directors, an increased effect in preventing sustained disability progression is one of the greatest unmet needs in RR-MS. Clinical data and the opinions of interviewed thought leaders indicate that Genzyme/Sanofi/Bayer HealthCare's emerging agent Lemtrada has demonstrated the potential to partially fulfill this unmet need.

Surveyed U.S. MCO pharmacy directors are also particularly receptive to new RR-MS therapies that offer a greater reduction in ARR over currently available therapies.

"We expect that several emerging agents, notably Lemtrada and potentially Roche/Genentech's ocrelizumab, will match the improvements on reduction in ARR that surveyed U.S. payers indicated would be required to achieve widespread inclusion and price premiums on MCO formularies," said Decision Resources Analyst John Crowley , Ph.D.

The report also finds that surveyed U.S. and European neurologists agree that reduction in ARR and the risk of serious or life-threatening sides effects are attributes that most influence their prescribing decisions in RR-MS—findings that likely underlie their positive outlook for Tecfidera.

Clinical data and the opinions of thought leaders interviewed by Decision Resources indicate that other emerging agents—Lemtrada, ocrelizumab and AbbVie/Biogen Idec's daclizumab—have advantages in reducing ARR over Teva's Copaxone, the sales-leading agent for treatment of RR-MS. The unique risk/benefit profiles of new therapeutic alternatives will be heavily scrutinized as neurologists incorporate them into the evolving MS treatment algorithm.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
2. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
3. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
4. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
5. Protected Classes Prescription Drug Mandates Would Hike Small Business Costs, Drug Company Profits
6. Though Over One-Third of Rheumatologists Have Prescribed Xeljanz for Their Rheumatoid Arthritis Patients, Physicians are Still Concerned With the Drugs Limited Post-Marketing Experience and Risks of Infection and Malignancy
7. Free Webinar Helps Physicians and Pharmacists Learn How to ePrescribe Controlled Substances
8. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
9. BioGenex and Abbott Molecular Conclude Successful Partnership
10. Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
11. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Story Highlights: ... the health care industry is causing providers to review ... Deloitte offers a suite of solutions for health care ... cost optimization: labor resource analysis, revenue cycle optimization and ... outcomes and better economics ...
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... today announced its strategic partnership with Connance, a healthcare industry leader providing ... companies’ proven, proprietary technology combine to provide health systems, hospitals and ambulatory ...
(Date:6/26/2016)... Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in ... in honor of the city’s history as home to some of the world’s leading ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
Breaking Medicine News(10 mins):